Form 4: Alto Neuroscience Executive Granted Stock Options

Michael Conick Hanley Jr., Chief Operating Officer of Alto Neuroscience, Inc., was granted employee stock options for 125,000 shares on February 5, 2025.

Summary

• Michael Conick Hanley Jr., the Chief Operating Officer of Alto Neuroscience, Inc., was granted employee stock options.
• The transaction occurred on February 5, 2025.
• The options grant covers 125,000 shares of Alto Neuroscience common stock.
• The exercise price of the options is $4.20 per share.
• The options vest over time, with 25% vesting on February 5, 2026, and the remainder vesting monthly over the following 48 months, contingent upon continuous service.
• The options expire on February 4, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders.

Positives

• The granting of stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the COO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry norms for similar-sized companies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the COO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, executive compensation, Alto Neuroscience, ANRO, Michael Conick Hanley Jr., COO